gi-hepatology
Fibrotic NASH Index (FNI) for NAFLD/NASH Fibrosis Prediction
Non-invasive index for predicting fibrotic NASH (F2-F4 fibrosis) in patients with non-alcoholic fatty liver disease. Alternative to liver biopsy for identifying patients with advanced NAFLD needing specialist monitoring.
References
- Palekar NA et al. A simple score for predicting fibrotic NASH using clinical and histologic data. Dig Dis Sci. 2006;51(9):1558-1563.
- EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Trimetazidine · Metabolic Anti-Anginal
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- L-Carnitine · Antidote / Metabolic Agent
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.